543 related articles for article (PubMed ID: 11266782)
21. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
22. The interaction properties of costimulatory molecules revisited.
Collins AV; Brodie DW; Gilbert RJ; Iaboni A; Manso-Sancho R; Walse B; Stuart DI; van der Merwe PA; Davis SJ
Immunity; 2002 Aug; 17(2):201-10. PubMed ID: 12196291
[TBL] [Abstract][Full Text] [Related]
23. The complexity of the B7-CD28/CTLA-4 costimulatory pathway.
Schweitzer AN; Sharpe AH
Agents Actions Suppl; 1998; 49():33-43. PubMed ID: 9426826
[TBL] [Abstract][Full Text] [Related]
24. Absence of B7-dependent responses in CD28-deficient mice.
Green JM; Noel PJ; Sperling AI; Walunas TL; Gray GS; Bluestone JA; Thompson CB
Immunity; 1994 Sep; 1(6):501-8. PubMed ID: 7534617
[TBL] [Abstract][Full Text] [Related]
25. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients.
Pistillo MP; Tazzari PL; Bonifazi F; Bandini G; Kato T; Matsui T; Nishioka K; Conte R; Ferrara GB
Transplantation; 2002 Apr; 73(8):1295-302. PubMed ID: 11981425
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival of rat to mouse cardiac xenografts with prolonged blockade of CD28-B7 interaction combined with peritransplant T-cell depletion.
Rehman A; Tu Y; Arima T; Linsley PS; Flye MW
Surgery; 1996 Aug; 120(2):205-12. PubMed ID: 8751584
[TBL] [Abstract][Full Text] [Related]
27. CD28-independent costimulation of T cells in alloimmune responses.
Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
[TBL] [Abstract][Full Text] [Related]
28. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
Fallarino F; Fields PE; Gajewski TF
J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
[TBL] [Abstract][Full Text] [Related]
29. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity.
Guinan EC; Gribben JG; Boussiotis VA; Freeman GJ; Nadler LM
Blood; 1994 Nov; 84(10):3261-82. PubMed ID: 7524733
[TBL] [Abstract][Full Text] [Related]
30. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
31. Blocking T-cell costimulation to prevent transplant rejection.
Zheng XG; Turka LA
Transplant Proc; 1998 Aug; 30(5):2146-9. PubMed ID: 9723421
[No Abstract] [Full Text] [Related]
32. Treatment of autoimmunity by inhibition of T cell costimulation.
Daikh DI; Wofsy D
Adv Exp Med Biol; 2001; 490():113-7. PubMed ID: 11505969
[No Abstract] [Full Text] [Related]
33. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
[TBL] [Abstract][Full Text] [Related]
34. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.
Boussiotis VA; Freeman GJ; Gribben JG; Nadler LM
Immunol Rev; 1996 Oct; 153():5-26. PubMed ID: 9010717
[No Abstract] [Full Text] [Related]
35. CD28-B7 T-cell co-stimulatory blockade potentiates the effects of intrathymic immunomodulation in sensitized graft recipients.
Stadlbauer TH; Schaub M; Korom S; Onodera K; Sayegh MH; Kupiec-Weglinski JW
Transplantation; 1997 Dec; 64(12):1816-22. PubMed ID: 9422425
[TBL] [Abstract][Full Text] [Related]
36. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
[TBL] [Abstract][Full Text] [Related]
37. The expanding world of co-stimulation: the two-signal model revisited.
Chambers CA
Trends Immunol; 2001 Apr; 22(4):217-23. PubMed ID: 11274928
[TBL] [Abstract][Full Text] [Related]
38. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
39. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
Zheng P; Wu Y; Guo Y; Lee C; Liu Y
Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
[TBL] [Abstract][Full Text] [Related]
40. Costimulation and its role in organ transplantation.
Bluestone JA
Clin Transplant; 1996 Feb; 10(1 Pt 2):104-9. PubMed ID: 8680045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
